H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Tempest Therapeutics (TPST) to $16 from $47 and keeps a Buy rating on the shares following the Q4 report. The firm sees ongoing financing risk of the company to move amezalpat into a pivotal study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST: